Savant Capital LLC Acquires New Shares in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)

Savant Capital LLC acquired a new stake in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 23,893 shares of the company’s stock, valued at approximately $72,000.

Several other institutional investors and hedge funds have also recently made changes to their positions in ZNTL. SG Americas Securities LLC raised its holdings in shares of Zentalis Pharmaceuticals by 84.8% in the third quarter. SG Americas Securities LLC now owns 26,149 shares of the company’s stock valued at $96,000 after acquiring an additional 11,997 shares in the last quarter. Wealth Enhancement Advisory Services LLC raised its holdings in Zentalis Pharmaceuticals by 44.3% in the third quarter. Wealth Enhancement Advisory Services LLC now owns 67,893 shares of the company’s stock worth $250,000 after purchasing an additional 20,848 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its holdings in Zentalis Pharmaceuticals by 63.9% in the third quarter. China Universal Asset Management Co. Ltd. now owns 13,676 shares of the company’s stock worth $50,000 after purchasing an additional 5,333 shares in the last quarter. Carson Advisory Inc. raised its holdings in Zentalis Pharmaceuticals by 55.8% in the third quarter. Carson Advisory Inc. now owns 24,570 shares of the company’s stock worth $90,000 after purchasing an additional 8,800 shares in the last quarter. Finally, GSA Capital Partners LLP raised its holdings in Zentalis Pharmaceuticals by 138.5% in the third quarter. GSA Capital Partners LLP now owns 608,585 shares of the company’s stock worth $2,240,000 after purchasing an additional 353,384 shares in the last quarter.

Zentalis Pharmaceuticals Stock Up 2.0 %

Shares of NASDAQ ZNTL opened at $2.53 on Thursday. The business’s 50 day moving average price is $2.58 and its 200 day moving average price is $3.09. The firm has a market cap of $180.29 million, a P/E ratio of -1.02 and a beta of 1.81. Zentalis Pharmaceuticals, Inc. has a 52 week low of $1.61 and a 52 week high of $18.07.

Insider Activity at Zentalis Pharmaceuticals

In related news, Director Jan Skvarka acquired 60,000 shares of the stock in a transaction on Friday, January 31st. The shares were acquired at an average price of $1.72 per share, for a total transaction of $103,200.00. Following the transaction, the director now owns 149,551 shares in the company, valued at approximately $257,227.72. This trade represents a 67.00 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Ingmar Bruns acquired 20,000 shares of the stock in a transaction on Thursday, February 6th. The stock was bought at an average price of $2.28 per share, for a total transaction of $45,600.00. Following the transaction, the insider now owns 36,629 shares in the company, valued at approximately $83,514.12. This represents a 120.27 % increase in their position. The disclosure for this purchase can be found here. 3.60% of the stock is owned by insiders.

Wall Street Analyst Weigh In

ZNTL has been the subject of a number of recent research reports. Guggenheim reduced their target price on shares of Zentalis Pharmaceuticals from $12.00 to $8.00 and set a “buy” rating for the company in a report on Friday, November 15th. UBS Group reduced their target price on shares of Zentalis Pharmaceuticals from $5.00 to $2.20 and set a “neutral” rating for the company in a report on Tuesday, January 28th. HC Wainwright reduced their target price on shares of Zentalis Pharmaceuticals from $20.00 to $10.00 and set a “buy” rating for the company in a report on Wednesday, January 29th. Wells Fargo & Company dropped their price target on Zentalis Pharmaceuticals from $8.00 to $6.00 and set an “equal weight” rating on the stock in a research note on Thursday, January 30th. Finally, Wedbush restated a “neutral” rating and set a $4.00 price target on shares of Zentalis Pharmaceuticals in a research note on Friday, January 24th. Five analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat, Zentalis Pharmaceuticals presently has a consensus rating of “Hold” and a consensus price target of $8.24.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.